Novo Nordisk (NVO, Financial) and Eli Lilly (LLY, Financial) are making headlines again—this time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.
Researchers at Washington University in St. Louis examined 215,000 U.S. military veterans with diabetes, comparing those using GLP-1 drugs with those on older treatments. The findings show reduced risks for 42 conditions, including psychotic disorders, seizures, and neurocognitive diseases like Alzheimer's and dementia. However, the study also flags higher risks for kidney issues, pancreatitis, and gastrointestinal conditions among GLP-1 users.
These findings emerge as the Biden administration moves forward with Medicare price negotiations for Ozempic and Wegovy. Meanwhile, Bristol-Myers Squibb (BMY) sees potential in its schizophrenia drug, Cobenfy, as a future Alzheimer's treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.